Powered by the Evidence-based Practice Centers
Evidence Reports All of EHC
Evidence Reports All of EHC



Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain

Systematic Review Jan 4, 2024

The following documents marked Previous version have not been added to the Previous Version report section!


In an effort to address the opioid epidemic, a prominent goal of current research is to identify alternative treatments with equal or better benefits for pain while avoiding potential unintended consequences that could result in harms.

This 'living' systematic review assesses the effectiveness and harms of cannabis and other plant-based treatments for chronic pain conditions. For the purposes of this review, plant-based compounds (PBCs) included are those that are similar to opioids in effect and that have the potential for addiction, misuse, and serious adverse effects; other PBCs such as herbal treatments are not included. The intended audience includes policy and decision makers, funders and researchers of treatments for chronic pain, and clinicians who treat chronic pain.

The literature is undergoing continuous surveillance, and the systematic review will be updated annually. Findings from the quarterly surveillance reports are available above in the Download Full Content bar.

In RCTs (mostly placebo controlled) of patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to <6 months):

  • Studies of cannabis-related products were grouped based on their tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio using the following categories: high-THC to CBD, comparable THC to CBD, and low-THC to CBD.
  • Comparable THC to CBD ratio oral spray is probably associated with small improvements in pain severity and overall function. There was no effect on serious adverse events. There may be a large increased risk of dizziness and sedation and a moderate increased risk of nausea.
  • Synthetic THC (high-THC to CBD) may be associated with moderate improvement in pain severity, no effect on overall function and increased risk of sedation, and large increased risk of nausea. Synthetic THC is probably associated with a large increased risk of dizziness.
  • Extracted whole-plant high-THC to CBD ratio products may be associated with large increases in risk of study withdrawal due to adverse events and dizziness.
  • Evidence on whole-plant cannabis (including patient’s choice of products), low-THC to CBD ratio products (topical CBD), other cannabinoids (cannabidivarin), and comparisons with other active interventions was insufficient to draw conclusions.
  • Other key adverse event outcomes (psychosis, cannabis use disorder, cognitive deficits) and outcomes on the impact on opioid use were not reported.
  • No evidence on other plant-based compounds such as kratom met criteria for this review.

Objectives. To update the evidence on benefits and harms of cannabinoids and other plant-based compounds to treat subacute and chronic pain in adults and adolescents using a living systematic review approach.

Data sources. Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Library, and SCOPUS® databases, and reference lists of included studies were searched to April 23, 2023.

Review methods. An updated protocol with expanded inclusion criteria (addition of sub-acute [4 to 12 weeks’ duration] pain and adolescents) was posted on the PROSPERO registry. We grouped studies based on their tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio and by product type, i.e. whole-plant (extracted or purified) or synthetic. We conducted random effects meta-analyses and categorized magnitude of benefit (large, moderate, small, or no effect [less than small]).

Results. Two new randomized controlled trials (RCTs) (n=115 and 15) and two new observational studies (N=2,071) were added for this annual update; no study addressed subacute pain or adolescents. One new RCT compared high and low THC to CBD ratio products versus placebo; the other new RCT evaluated was very small and had methodological limitations. Since the inception of this living review, from 5,228 total abstracts identified, 23 RCTs (N=2,035) and 10 observational studies (N=15,840) assessing different cannabinoids were included; no study evaluated kratom. Studies were primarily short term, and 58 percent enrolled patients with neuropathic pain. Comparators were primarily placebo or usual care. Strength of evidence (SOE) was low unless indicated otherwise.

Compared with placebo, plant-extracted comparable ratio THC to CBD oral spray was associated with a small decrease in pain severity (7 RCTs, N=632, 0 to 10 scale, mean difference [MD] −0.54, 95% confidence interval [CI] −0.95 to −0.19, I2=39%; SOE: moderate) and a small decrease in overall function (6 RCTs, N=616, 0 to 10 scale, MD −0.42, 95% CI −0.73 to −0.16, I2=32%; SOE: moderate) versus placebo. There was no effect on study withdrawals due to adverse events. There was a large increased risk of dizziness and sedation, and a moderate increased risk of nausea (dizziness: 6 RCTs, N=866, 31.0% vs. 8.0%, relative risk [RR] 3.57, 95% CI 2.42 to 5.60, I2=0%; sedation: 6 RCTs, N=866, 8.0% vs. 1.2%, RR 5.04, 95% CI 2.10 to 11.89, I2=0%; and nausea: 6 RCTs, N=866, 13.9% vs. 7.5%, RR 1.79, 95% CI 1.19 to 2.77, I2=0%).

Synthetic high-THC to CBD ratio products were associated with a small improvement in pain severity, a moderate increase in sedation, and a large increase in risk of nausea following the addition of one new RCT (pain: 7 RCTs, N=448, 0 to 10 scale, MD −0.95, 95% CI −1.81 to −0.25, I2=60%; sedation: 4 RCTs, N=386, 19.5% vs. 11.5%, RR 1.60, 95% CI 1.01 to 2.95, I2=8%; nausea: 3 RCTs, N=353, 11.1% vs. 5.2%, RR 2.22, 95% CI 0.90 to 5.05; I2=0%). There was also moderate SOE for a large increased risk of dizziness (3 RCTs, N=353, 28.9% vs. 11.0%, RR 2.52, 95% CI 1.20 to 4.82, I2=41%). Extracted whole-plant high-THC to CBD ratio products (oral) were associated with a large increased risk of study withdrawal due to adverse events (1 RCT, 13.9% vs. 5.7%, RR 3.12, 95% CI 1.54 to 6.33) and dizziness (1 RCT, 62.2% vs. 7.5%, RR 8.34, 95% CI 4.53 to 15.34); outcomes assessing benefit were not reported or insufficient.

Evidence (including observational studies) on whole-plant cannabis, topical or oral CBD, low-THC to CBD ratio products (2 new RCTs), other cannabinoids, comparisons with active non-cannabis treatments or between cannabis-related products, and impact on use of opioids also remained insufficient. Evidence was not available on important harms such as psychosis, cannabis use disorder, and cognitive effects.

Conclusions. Low to moderate strength evidence suggests small improvements in pain (mostly neuropathic), and moderate to large increases in common adverse events (dizziness, sedation, nausea) with high and comparable THC to CBD ratio extracted cannabinoids and synthetic products versus placebo during short-term treatment (1 to 6 months) in adults with chronic pain. Evidence for low-THC to CBD ratio products, whole-plant cannabis, and other comparisons, outcomes, and plant-based compounds was unavailable or insufficient to draw conclusions.

Summary of
Clinical and Policy
Caveats, Applicability,
and Limitations

This summarizes benefits and harms in the short term (4 weeks to <6 months) based on our original review and the four subsequent literature updates. Updates have added two studies to our list of included studies without changing our conclusions. The evidence for synthetic THC (high THC to CBD ratio) was previously rated as insufficient. Upon re-reviewing the evidence from one small (n=26), low risk of bias RCT, it was judged to provide low strength of evidence.

Intervention Pain Response more information Pain Severity more information Function more information
Comparable THC/CBD – Oromucosal Spray new tab Potential effecta

4 Studies

low SOE

Small effect

7 Studies

moderate SOE
Moderate SOE

Small effect

6 Studies

moderate SOE
Moderate SOE

High THC – Synthetic, Oral new tab Moderate effectb

1 Study

low SOE

Moderate effect

6 Studies

low SOE

No effect

3 Studies

low SOE

High THC – Extracted From Whole Plant, Oral new tab No evidence Insufficient

2 Studies


1 Study

Low THC – Topical CBD new tab No evidence Insufficient

1 Study

No evidence
Low THC – Oral CBD new tab No evidence Insufficient

1 Study


1 Study

Other Cannabinoids – CBDV, Oral new tab Insufficient

1 Study


1 Study

No evidence
Whole-Plant Cannabis (12% THC)cnew tab No evidence Insufficient

1 Study

No evidence
Abbreviations: CBD = cannabidiol; CBDV = cannabidivarin; SOE = strength of evidence; THC = tetrahydrocannabinol.
a Potential effect: SOE of low or higher; findings indicate at least a small magnitude of effect but not statistically significant.
b The evidence for synthetic THC (high THC to CBD ratio) was previously rated as insufficient. Upon re-reviewing the evidence from one small (n=26), low risk of bias RCT, it was judged to provide low strength of evidence.
c Comparison was "usual care."
Effect size: None (i.e., no effect/no statistically significant effect), small, moderate, or large increased benefit.
Where links are available within the Report Snapshot tables, clicking the link will take you to the PubMed listing for the studies available within PubMed. Not all studies in all findings are available in PubMed.

This review addresses the following Key Questions (KQs):

KQ 1: In adults with chronic pain, what are the benefits of cannabinoids for treatment of chronic pain?

KQ 2: In adults with chronic pain, what are the harms of cannabinoids for treatment of chronic pain?

KQ 3: In adults with chronic pain, what are the benefits of kratom or other plant-based substances for treatment of chronic pain?

KQ 4: In adults with chronic pain, what are the harms of kratom or other plant-based substances for treatment of chronic pain?

Organizing principle of cannabis-related studies based on ratios of THC to CBD

Intervention Category Definition Possible Derivatives Example Products
High-THC THC to CBD ratio equals ≥2:1 ratio Synthetic, extracted or purified from whole-plant, whole-plant Synthetic: dronabinol/Marinol®, nabilone/Cesamet® Extracted: THC oil (oral)
Low-THC THC to CBD ratio equals 1:≥2 ratio Extracted or purified from whole-plant, whole-plant CBD topical cream or ointment; cannabis flowers, buds, leaves
Comparable THC to CBD THC to CBD ratio is between threshold for high-THC and low-THC categories Extracted or purified from whole-plant, whole-plant Nabiximols (Sativex®)
Whole-plant Cannabis Products Potentially unknown THC to CBD ratio; categorized based on information provided Whole-plant or parts/materials from the plant, not extracted, purified, or synthetic Cannabis flowers, resins, buds, leaves, hashish
Other Cannabinoids Interventions testing cannabinoids other than THC and/or CBD Extracted or purified from whole-plant Extracted oils (oral)
Abbreviations: CBD = cannabidiol; THC = tetrahydrocannabinol. a Nabilone included in this category.

Definitions of effect sizes

Effect Size Definition
Small effect
  • MD 0.5 to 1.0 points on a 0 to 10-point scale, 5 to 10 points on a 0 to 100-point scale
  • SMD 0.2 to 0.5
  • RR/OR 1.2 to 1.4
Moderate effect
  • MD >1 to 2 points on a 0 to10-point scale, >10 to 20 points on a 0 to 100-point scale
  • SMD >0.5 to 0.8
  • RR/OR 1.5 to 1.9
Large effect
  • MD >2 points on a 0 to10-point scale, >20 points on a 0 to 100-point scale
  • SMD >0.8
  • RR/OR ≥2.0
Potential effect Findings with small or larger magnitude of effect, not statistically significant; but with SOE rating of Low or higher (downgraded mainly for imprecision)
No effect No effect/no statistically significant effect
Abbreviations: MD = mean difference; OR = odds ratio; RR = relative risk; SMD = standardized mean difference.

Implications for Clinical Practice, Education, Research, or Health Policy

The implications of the present findings for clinical practice are mixed. These results suggest that select individuals with chronic neuropathic pain may experience moderate short-term improvements in pain when using cannabis products (synthetic or extracted from whole-plant) that have a high-THC to CBD ratio. The impact of this intervention on moderate or long-term outcomes is unknown. Cannabis products with a comparable THC to CBD ratio may also result in small improvements in pain severity. Those who take products containing comparable or high ratios of THC are also at increased risk for adverse events, including dizziness, sedation and nausea. The expected benefit of this treatment is comparable to prescription opioids, several nonopioid medications, and nonpharmacological interventions. The evidence on adverse events with cannabis-related products is much less robust than the evidence on similar outcomes with opioids or nonopioid medications. The risk of sedation and dizziness appears similar with cannabis-related products, opioids, and the anticonvulsants pregabalin and gabapentin, while the risk for nausea appears to be larger with opioids and the antidepressant duloxetine than with cannabis-related products. These are only indirect comparisons, with very limited evidence on cannabis products relative to the other drugs, and comparisons of effects on serious and long-term harms are not possible even indirectly. Understanding how cannabis products' adverse event profiles compare with other available treatments for chronic pain, particularly opioid and non-opioid medications, is essential to determining the benefit to harm ratio. However, the strength of this evidence is mostly low, and more data are needed to confidently recommend this as a treatment for various chronic pain-related conditions or for patients with diverse demographic or clinical characteristics.

As noted in the limitations above, baseline use of opioids for pain and the impact of cannabinoids on the use of opioids for pain were very poorly reported. In an effort to address the opioid epidemic, a prominent goal of current research is to identify alternative treatments with equal or better benefits for pain while avoiding potential unintended consequences that could result in harms. Unfortunately, much of the findings to date are low SOE or insufficient evidence, and more high-quality studies are needed.

Our synthesis of the evidence leads to several important additional questions that could be addressed most effectively in a clinical practice guideline. Examples of questions that could be best addressed through a guideline process include: At what point in the treatment decision tree should cannabis-based medicines be considered? How should patient preferences be taken into account? What are pragmatic dosing guidelines? And finally, what are the comparative effects on costs of care?

Implications for Future Research

The gaps in the research evidence that are outlined above lead to specific recommendations for conducting future studies that will improve the strength of the conclusions that can be drawn, and provide better guidance for policymakers, clinicians and patients alike.

PICOTS Element Gap in Evidence Suggested Future Research
  • Non-White populations, older adults, women
  • Pain conditions other than neuropathic pain
  • Studies to assess possible differential effects in different races or ethnicities
  • Stratified analyses according to sex, including effects in pregnant and lactating persons
  • Studies to assess effects based on age differences
  • Pain populations expanded to include persons with non-neuropathic chronic pain, specifically back pain, other musculoskeletal pain, and fibromyalgia
  • High THC to CBD ratio from plant origin (not synthetic)
  • Comparable THC to CBD ratio formulations other than oromucosal spray
  • Low THC to CBD ratios, whole-plant cannabis, and other cannabinoids
  • Kratom
  • Studies of high THC to CBD ratio products derived from whole-plant cannabis, with clear description of extraction or purification process and consistent nomenclature regarding the final product
  • Studies to compare different routes of administration (e.g., oromucosal spray, oral oil, oral capsule, smoked, etc.)
  • Studies should include and compare standardized treatment plans
  • Exploration of effects of different cannabinoids
  • Studies to asses kratom and/or other plant-based treatments
  • Head-to-head comparisons
  • Studies comparing plant-based interventions with other plant-based treatments, opioids, non-opioid medications, or nonpharmacological interventions to evaluate active-control comparisons to provide direct evidence on comparative effectiveness
  • Pain response (>30% improvement in pain severity)
  • Overall function, quality of life
  • Depression, anxiety, sleep, opioid use
  • Adverse event outcomes
  • Outcomes should be consistently defined and reported across studies; ideally a core set of outcomes should be developed for future studies of treatments for chronic pain.
  • Future studies should include pain response, measures of overall function, and adverse events (overall, serious, and withdrawals due to adverse events at a minimum), in addition to changes in pain severity.
  • Patient-centered and patient-reported outcomes (e.g., QOL, depression, anxiety, and sleep) should be measured using validated tools for diagnosis and measurement of change.
  • In addition to reporting on opioid use prior to study enrollment, future studies should report on use of opioids, and other pain medications, during the trial. In particular, there is a need for more information on possible opioid sparing effects of plant-based treatments.
  • Studies need to assess serious harms such as development of cannabis use disorder, psychosis, and cognitive deficits. Other adverse events (e.g. sexual dysfunction) may need to be studied as new data emerge.
  • Limited evidence on studies >6 weeks in duration
  • Considering the chronic nature of the conditions, studies should provide followup assessments at longer timepoints, e.g., ≥3, 6 or 12 months
Study Design
  • RCTs and cohort studies with adequate sample sizes to evaluate all important outcomes
  • Cohort studies with adequate control for confounding, ascertainment of exposures and outcomes
  • RCT and cohort studies with low risk of bias
  • All Designs:
    • Studies with larger sample sizes to adequately power statistical analyses for key outcomes are needed across all interventions except the synthetic medications
    • Should be designed and powered a priori to conduct subgroup analyses on important factors such as race, age, sex, and type of product or dose where these are variable
  • Cohort studies:
    • Should be conducted prospectively where possible, and conduct and report on ascertainment and validation of exposure and outcomes following best-practice guidance74
    • Should use appropriate methods to control for confounding on prognostic factors (e.g., baseline pain, prior and continued use of other interventions for pain, psychiatric illnesses)
  • RCTs:
    • Should not use run-in periods, or enriched enrollment randomized withdrawal designs that may overestimate effects and limit the generalizability of the findings75
    • Should be conducted using the parallel design (not crossover)
  • Systematic Reviews
    • As more evidence emerges, analyses should stratify and conduct subgroup analyses based on product specifics, pain conditions, and population characteristics.
Abbreviations: CBD = cannabidiol; RCT = randomized controlled trial; THC = tetrahydrocannabinol.

This review does not provide cost information.

Strengths and Limitations

The evidence base on cannabis and other plant-based treatments for chronic pain has multiple important limitations. Eighty percent of trials enrolled patients with chronic pain due to a neuropathic cause (7 in patients with multiple sclerosis, 4 with a mix of conditions or not specified, 2 with diabetic neuropathy, and 1 each with chemotherapy, HIV, or spinal cord injury). There is little or no evidence on other types of chronic pain, including low back pain, osteoarthritis, fibromyalgia, and inflammatory arthritis. In terms of age, there is limited evidence on younger and older populations, with most patients being middle-aged (mean age 52 years). Studies generally excluded patients with a history of psychiatric disorders other than prior history of depression or anxiety. Importantly, there was either no evidence or inadequate evidence to evaluate important patient populations based on sex/gender, race/ethnicity, age, or pregnancy/lactating status.

Another limitation is the lack of consistent nomenclature detailing the interventions and products studied. For example, products are described as extracted in some studies, but without a consistent way of describing the process or the resulting purity of the products. Other studies used words such as "standardized" to describe the amount of THC in a whole-plant cannabis product, again with lack of description of how this was defined or determined. Studies did not consistently report the ratio of THC to CBD in the products, particularly outside of the products that are close to a 1 to 1 ratio (oromucosal spray, Sativex). Other limitations include the complete lack of evidence on other plant-based compounds like kratom, no RCT evidence on whole-plant cannabis products, and only a single, small study each for topical CBD or cannabinoids other than THC or CBD.

Change in pain severity was the most commonly reported outcome. Other important outcomes were mainly not reported or inconsistently reported or defined. Pain response, defined as a 30 percent or greater improvement in pain, was reported in 5 of 23 studies (22%); 6 of 23 studies (26%) reported specifically on pain interference, and 8 of 23 (35%) reported measures of physical function or disability. The studies poorly reported baseline use of opioids for pain, and only one high risk of bias observational study reported the impact of cannabis interventions on changes to prescription opioid use. While almost all studies reported the number of patients who withdrew from studies due to adverse events, 30 percent did not report serious adverse events, and 65 percent did not report the overall adverse events, particularly by group. When serious adverse events were reported, studies either used a unique definition, or did not provide one. In reporting on specific adverse events, not all studies were clear about whether the events were the number of individuals with at least one event, or if a single patient could contribute to an event more than once. Other adverse events that have been reported in noncomparative observational studies and were prioritized for this review (development or exacerbation of psychosis, CUD, and cognitive deficits) were not reported.

Trials were limited by study design and small sample sizes (range 9 to 339; mean 89), particularly for assessing harms. The SOE of the findings was very commonly downgraded due to imprecise estimates as a result of too few patients enrolled (see Appendix G). There were also differences in some key baseline characteristics, including baseline pain scores, which were frequently not adjusted for in study analyses. Another methodologic concern is that many conclusions in the included studies were drawn from post-hoc analyses. Study durations were short-term and included less than 6 months followup; 37 percent of studies were 4 to 6 weeks long. This is a key limitation, as pain severity in patients with chronic pain may vary substantially in the short-term and may be influenced temporarily by an intervention or treatment; it is most useful to understand the enduring impact of a treatment on pain severity. Similarly, adverse events such as CUD, cognitive deficits, and serious adverse events may take time to develop and longer studies are required to capture such events. Well-designed head to head studies comparing a plant-based product with a standard of care treatment for chronic pain are lacking. The current evidence consists only of small, poorly designed, crossover or observational studies.

Despite limitations in the evidence base, our review has several strengths. First the living systematic review approach allows us to add new studies soon after they are published, thereby providing an opportunity to update conclusions in a rapid fashion. This may be important as cannabis and other plant-based treatments become more readily available to patients, providers and researchers. Also, using an organizational framework that categorizes cannabis-related products by both their THC and CBD ratios and their origin (plant-based versus synthetic) allows a way to conceptualize the evidence on these two prominent cannabinoids that is consistent with how they are available to consumers. A final strength that separates this review from others is the exclusion of very short-term studies (e.g., a small number of dosing sessions), improving the applicability of the findings to chronic pain.

There are also some limitations to our review process. We excluded non-English language publications and study results published only as abstracts. We categorized nabilone as a synthetic high-THC product though it is more accurately described as a synthetic cannabinoid – a chemical analog to THC, and could have differing effects to THC. To address this possibility, we performed stratified analyses among outcomes that were pooled for synthetic high-THC interventions. The effect size for change in pain severity was larger with nabilone than with dronabinol, but the difference between the effect sizes was not statistically significant. Our inclusion criteria required that the study population have chronic pain, or have subgroup analyses for this group, which may be why we did not find evidence related to kratom. We were unable to assess publication bias (small sample size bias) for most outcomes, as most meta-analyses included fewer than eight studies. The exception was the analysis of change in pain severity with high-THC interventions, where we were unable to rule out important publication bias. Additional studies are needed to clarify the effect size estimates and our confidence in the findings. Since this is a living systematic review, new evidence will be incorporated into the review and findings updated on a regular basis. As in other recent systematic reviews of interventions to treat chronic pain, we grouped the magnitude of effects into small, moderate and large effects, rather than according to published minimal clinically important difference (MCID) thresholds. Defining clinical significance in chronic pain is difficult because it is subjective and difficult to correlate with real-life experiences of patients. For example, the MCID for improvement in pain is 15 points on a 0 to 100 scale. However, interventions commonly used for chronic pain, including opioids and nonsteroidal anti-inflammatory drugs do not achieve this level of reduction.11,12 The typical reduction with opioids, nonopioid medications, nonpharmacological interventions, and cannabinoids is small, 5 to 10 points and may be considered a clinically important effect by patients and clinicians.


A number of factors could impact the applicability of our findings. The evidence currently is most applicable to patients with neuropathic pain with mostly moderate to severe pain (mean baseline score was 6.6 on a 0 to 10 scale, with a range of 4 to 7.9). There is also considerable variability within the included studies among the types of neuropathic pain patients experience, and treatment effects might be different depending on the specific neuropathic pain condition.

The evidence base is generally applicable to women with around 71 percent of enrolled participants being female. While the age range across studies was broad, 18 to 84 years, the evidence is mainly applicable to middle-aged patients (mean age 50 years). Currently, the evidence is poorly applicable to patients of non-White race. It is also unclear how the evidence applies to patients currently taking prescription opioids to treat chronic pain or patients with serious mental illness or other comorbidities who are often excluded from trials. In terms of interventions, this evidence is applicable to comparable THC to CBD ratio oromucosal spray and to high-THC synthetic medications. The evidence for comparable THC to CBD oral spray is applicable to mean dosing of 8.4 sprays per day (21 mg THC/23 mg CBD). The evidence for high-THC to CBD ratio synthetic drugs applies to dosing that was titrated upward, with a maximum dose of 15 to 20 mg per day of dronabinol and 0.5 to 2 mg per day of nabilone (mean doses not reported). For high-THC to CBD products extracted from whole-plants, the evidence was too heterogeneous and limited (2 RCTs) to describe an applicable dose. Applicability to other products including whole plant cannabis is very low or non-existent.

This evidence applies to short-term treatment and mainly informs the impact on mean changes in pain severity and common adverse events. The outcomes after longer term treatment may be different and could influence other outcomes not considered in short-term studies included here (e.g. psychosis, CUD, cognitive deficits). None of the studies reported other information relevant for assessing applicability, such as the description of the source of potential study participants or the number of women randomized relative to the number of women enrolled.

Although 60 percent of studies were conducted in the United States, we were unable to assess the impact of country of study or other geographic location characteristics (e.g., rural, metropolitan) on the applicability of specific results.

A number of evidence gaps or limitations in the evidence potentially impacted the applicability of our findings including lack of evidence on extracted whole-plant or purified interventions, whole-plant cannabis, and kratom.

McDonagh MS, Morasco BJ, Wagner J, et al. Cannabis-based products for chronic pain: a systematic review. Ann Intern Med. 2022 Aug;175(8):1143-53. Epub 2022 Jun 7. PMID: 35667066. DOI: 10.7326/M21-4520.

Chou R, Ahmed AY, Bougatsos C, Morasco BJ, Dana T, Fu R. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update—Surveillance Report 2. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 75Q80120D00006.) AHRQ Publication No. 24-EHC006. Rockville, MD: Agency for Healthcare Research and Quality; January 2024. DOI: https://doi.org/10.23970/AHRQEPCCER250.2023UPDATESR2. Posted final reports are located on the Effective Health Care Program search page.

As this report is a living systematic review, several versions are available. You can click to view the previous versions below. To find the latest version, please look in the Downloads section.

Previous Versions Last Date Searched Publication Date
Early July 2023 September 20, 2023
April 23, 2023 August 31, 2023
April 2023 July 2023
January 2023 April 2023
October 2022 January 2023
July 2022 September 2022
April 2022 September 2022
March 2022 June 2022
January 2022 May 2022
October 2021 January 2022
mid-August 2021 October 2021
July 2021 October 2021
Page last reviewed January 2024
Page originally created January 2021

Internet Citation: Systematic Review: Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain. Content last reviewed January 2024. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.

Select to copy citation